Search results for "Medical therapy"

showing 10 items of 17 documents

Subtotal esophageal resection in motility disorders of the esophagus.

2005

<i>Background:</i> Esophagectomy for motility disorders is performed infrequently. It is indicated after failed medical therapy, pneumatic dilation, non-resecting surgical and redo procedures. Patient selection in this group is challenging and the operative risk has to be weighted carefully against the poor quality of life with persistent or recurrent dysphagia. <i>Patients and Methods:</i> Between September 1985 and April 2004, subtotal esophageal resections for advanced esophageal motility disorders of the esophagus not responding to previous therapy were carried out in 8 patients (6 females, 2 males). The median age of these patients was 59.5 (43–78) years. Six pa…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMotilityResectionMedicineHumansEsophageal Motility DisordersEsophagusIntestinal MucosaAgedRetrospective StudiesPneumatic dilationHyperplasiabusiness.industryGeneral surgeryGastroenterologyMuscle SmoothGeneral MedicineLong term resultsMiddle AgedSurgeryEsophagectomyRadiographymedicine.anatomical_structureTreatment OutcomeEsophagectomyFemalebusinessMedical therapyFollow-Up StudiesDigestive diseases (Basel, Switzerland)
researchProduct

Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a histor…

2021

Abstract Background A patent foramen ovale (PFO) is formed when the ovale foramen does not close spontaneously or re-opens leaving the right and left atrium connected. The present study was conducted to analyze the cost-effectiveness of PFO closure with Amplatzer device plus medical therapy (MT) compared to MT alone in the French reimbursement system for PFO patients with a prior history of stroke, using the RESPECT study data. Methods A multi-state Markov model was used. The analysis was conducted from a collective perspective over a 10-year time horizon with 4% discount applied for costs and health effects. The simulated population included adult patients with PFO. Sub-group analysis was …

Adultmedicine.medical_specialtyCardiac CatheterizationSeptal Occluder DeviceCost-Benefit AnalysisPopulationForamen Ovale PatentRecurrenceInternal medicineForamenmedicineSecondary PreventionHumansIn patienteducationStrokehealth care economics and organizationseducation.field_of_studybusiness.industryCost-effectiveness analysismedicine.diseaseQuality-adjusted life yearStrokeTreatment OutcomeCardiologyPatent foramen ovaleQuality-Adjusted Life YearsCardiology and Cardiovascular MedicinebusinessMedical therapyJournal of cardiology
researchProduct

Ulipristal acetate versus leuprolide acetate for uterine fibroids

2012

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleed…

Adultmedicine.medical_specialtyUterine fibroidsIntention to Treat AnalysiUrologyAdministration OralEndometriumInjections Intramuscularlaw.inventionchemistry.chemical_compoundYoung AdultEndometriumPrimary outcomeRandomized controlled trialDouble-Blind MethodlawUlipristal acetateSelective progesterone receptor modulatormedicineUterine NeoplasmUlipristalMenorrhagiaGynecologyIntention-to-treat analysisLeiomyomabusiness.industryObstetrics and GynecologyUterine bleedingUterine fibroids uterine leiomyomas uterine bleeding ulipristal acetate leuprolide acetate medical therapyGeneral MedicineNorpregnadieneMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciamedicine.anatomical_structurechemistryAmenorrheaFemalemedicine.symptomLeuprolidebusinessHuman
researchProduct

Teprotumumab for the treatment of active thyroid eye disease

2020

Abstract Background Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration–approved medical therapy is available...

Drugmedicine.medical_specialtyBlindingmedia_common.quotation_subjectEye diseaseMedizin030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOphthalmologymedicine030212 general & internal medicinemedia_commonTeprotumumabbusiness.industryThyroidGeneral Medicinemedicine.diseaseDermatologyeye diseasesClinical trialmedicine.anatomical_structuresense organsbusinessMedical therapymedicine.drug
researchProduct

Hyaluronic acid-based two-stage medical therapy to unfold the aged face: The centrifugal approach

2020

Background: Facial aging is a multifactorial process characterized by structural changes to the dermis and ligaments, lipoatrophy in the fat pads and hypodermis, remodeling of the bony skeleton, change in muscle tonicity and tissue descent. Aims: The purpose of this study is to evaluate the efficacy of a hyaluronic acid-based treatment for the aging face that addresses all its causes in a caudal to cranial and medial to lateral direction: the centrifugal technique. Methods: Between March 2015 and January 2018, 187 patients were treated with a high G’ hyaluronic acid in two sessions, one/two weeks apart, to improve signs of facial aging, starting from the lower centrofacial area and progress…

Facial rejuvenationSettore MED/19 - Chirurgia PlasticaDentistryCosmetic TechniquesDermatology030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDermisfacial rejuvenationHyaluronic acidhyaluronic acidHumansRejuvenationMedicineStage (cooking)LipoatrophyAgedmidface agingbusiness.industrymedicine.diseaseSkeleton (computer programming)Nasolabial foldSkin AgingTreatment Outcomemedicine.anatomical_structurechemistryPatient Satisfaction030220 oncology & carcinogenesisnasolabial foldbusinessMedical therapy
researchProduct

Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm

2007

Botulinum toxin (BTX) is the medical therapy of choice in hemifacial spasm (HFS). However, in some patients, its therapeutic effect is insufficient. ### Patient 1. A 64-year-old man with a 10-year history of left-sided HFS was treated with BTX over a period of 6 years with good results. However, in the last 2 years the spasms were never sufficiently relieved by BTX. The patient felt significantly impaired, but declined to undergo neurosurgical intervention. The EDB test showed a decrease in the CMAP amplitude of 60%. Without changing the BTX regime, pregabalin (initially 75 mg/day increased every 5 days by 75 mg to 150 mg twice daily) was added for a 1-month trial period in the absence of a…

MaleBotulinum ToxinsPregabalinPregabalinPhysiology (medical)medicineHumansHemifacial SpasmAdverse effectgamma-Aminobutyric AcidAnti-Dyskinesia Agentsbusiness.industryTherapeutic effectMiddle Agedmedicine.diseaseBotulinum toxinSensory SystemsDiscontinuationDrug CombinationsTreatment OutcomeAdd on treatmentNeurologyAnesthesiaAnticonvulsantsFemaleNeurology (clinical)businessMedical therapymedicine.drugHemifacial spasmNeurology
researchProduct

Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?

2012

To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy.3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976-96, 1997-2004 and 2005-09) were considered.The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p0.001). Median relative survival increased from 5.9 months during the 1976-96 period to 10.2 months during the 1997-2004 period but, d…

MaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatmentPopulationAntineoplastic AgentsPopulation basedHealth Services AccessibilityInternal medicinemedicineHumansMolecular Targeted TherapyRegistriesHealthcare DisparitieseducationAgedClinical Trials as TopicChemotherapyeducation.field_of_studyEvidence-Based MedicineMedical treatmentbusiness.industryPatient SelectionPalliative CareAge FactorsTreatment optionsMiddle Agedmedicine.diseaseSurvival AnalysisSurvival RateClinical trialTreatment OutcomeOncologyFemaleFranceDiffusion of InnovationColorectal NeoplasmsbusinessMedical therapyEuropean Journal of Cancer
researchProduct

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Uric acid, phosphate and oxalate stones: treatment and prophylaxis.

2004

Medical treatment for the most commonly encountered types of renal stones is described. Nowadays treatment for uric acid stones is well-defined: alkalinizing urine is easy with drugs that are sufficiently active and well enough managed. Relapse is avoided in a high percentage of patients. Medical treatment of phosphate or calcium stones is a more open question as results are far from satisfactory compared with intra- and extra-corporeal approaches which are often minimally invasive and well accepted by both patient and urologist. Relapses are not easy to control because prophylactic measures such as changes in lifestyle and diet are never activated or because they are adopted for a brief pe…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentCalcium oxalateUrineLithotripsyRisk AssessmentOxalatechemistry.chemical_compoundKidney CalculiPharmacotherapyLithotripsymedicineHumansCalcium Oxalatebusiness.industryPhosphatePrognosisSurgeryUric AcidchemistryUric acidDrug Therapy CombinationFemalebusinessMedical therapyUrologia internationalis
researchProduct

Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions

2015

Background Through contemporary literature, the optimal strategy to manage coronary chronic total occlusions (CTOs) remains under debate. Objectives The aim of the Italian Registry of Chronic Total Occlusions (IRCTO) was to provide data on prevalence, characteristics, and outcome of CTO patients according to the management strategy. Methods The IRCTO is a prospective real world multicentre registry enrolling patients showing at least one CTO. Clinical and angiographic data were collected independently from the therapeutic strategy [optimal medical therapy (MT), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)]; a comparative 1-year clinical followup was pe…

Malemedicine.medical_specialtymedicine.medical_treatmentLeftCoronary AngiographyVentricular Dysfunction LeftCoronary artery bypass surgeryPercutaneous Coronary InterventionInternal medicineVentricular DysfunctionPrevalenceHumansMedicineProspective StudiesRegistriesMyocardial infarctionCoronary Artery BypassProspective cohort studyCABGAgedbusiness.industryChronic total occlusion † Registry † PCI † CABG † Optimal medical therapyPercutaneous coronary interventionCardiovascular AgentsPCImedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareChronic total occlusionTreatment Outcomemedicine.anatomical_structureCoronary OcclusionItalyCoronary occlusionChronic total occlusion; PCI; CABGChronic DiseaseCardiovascular agentConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryEuropean Heart Journal
researchProduct